Results 211 to 220 of about 5,702,760 (334)

Characterizing epithelial‐mesenchymal transition‐linked heterogeneity in breast cancer circulating tumor cells at a single‐cell level

open access: yesMolecular Oncology, EarlyView.
In over 50% of non‐metastatic breast cancer patients, circulating tumor cells (CTCs) along the whole epithelial‐mesenchymal transition spectrum are detected. Total CTC number and individual phenotypes relate to aggressive disease characteristics, including lymph node involvement and higher tumor proliferation. At the single‐cell level, mesenchymal CTCs
Justyna Topa   +14 more
wiley   +1 more source

Aggressive prostate cancer is associated with pericyte dysfunction

open access: yesMolecular Oncology, EarlyView.
Tumor‐produced TGF‐β drives pericyte dysfunction in prostate cancer. This dysfunction is characterized by downregulation of some canonical pericyte markers (i.e., DES, CSPG4, and ACTA2) while maintaining the expression of others (i.e., PDGFRB, NOTCH3, and RGS5).
Anabel Martinez‐Romero   +11 more
wiley   +1 more source

The MACHO Project LMC Variable Star Inventory: Classical Cepheids and AGB Variables [PDF]

open access: green, 1998
D. R. Alves   +20 more
openalex   +1 more source

Tumor and germline testing with next generation sequencing in epithelial ovarian cancer: a prospective paired comparison using an 18‐gene panel

open access: yesMolecular Oncology, EarlyView.
Genetic testing in epithelial ovarian cancer includes both germline and tumor‐testing. This approach often duplicates resources. The current prospective study assessed the feasibility of tumor‐first multigene testing by comparing tumor tissue with germline testing of peripheral blood using an 18‐gene NGS panel in 106 patients.
Elisabeth Spenard   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy